Ribbon Biolabs
Ribbon Biolabs is a Vienna-based synthetic biology company that provides cell-free synthetic DNA products (MiroSynth™ and MiroMine™) to R&D teams in mRNA therapies, vaccines, cell and gene therapies, protein engineering, and gene editing.
- Company typePrivate
- Founded2018
- HeadquartersVienna, Austria
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ribbon Biolabs does
Ribbon Biolabs is a Vienna, Austria-based synthetic biology company founded in 2018 that operates a proprietary cell-free DNA synthesis platform designed to bypass traditional bacterial cloning workflows. The company's core commercial product, MiroSynth™ Cell-Free DNA, is built without bacteria and is positioned to eliminate bacterial contaminants, residual host DNA, cloning-based delays, and design compromises caused by toxicity or instability in bacterial systems. A second product, MiroMine™, is a kit-based cell-free DNA synthesis offering currently in beta that enables on-site construction of complex DNA without cloning.
The company targets research and development teams across mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing. It cites industry pain points including sequences that traditional providers cannot manufacture (claimed to affect 84% of teams) and rejections driven by complexity or length limits (50% of rejections), and notes that 75% of teams in mRNA, CAR-T, and vaccines prefer cell-free DNA. Its go-to-market is product-led, with MiroSynth sold via direct enterprise engagement initiated through the website and MiroMine accessed through a beta application.
Ribbon Biolabs is a privately held company with 51-100 employees, based in Vienna. It has raised approximately $20.2 million in disclosed institutional funding, led by Hadean Ventures with participation from Helicase Venture, Lansdowne Partners, tecnet equity, and XISTA Science Ventures. The leadership team includes CEO Jodi Barrientos, founders Wladimir Labeikovsky and Harold P. de Vladar, Executive Chairman Roopom Banerjee, Chair Dr. Urs Spitz, and Vice President, Global Head of Sales Jeff Fitzgerald. Pricing is not publicly disclosed, and no customer logos are listed in available sources.
Ribbon Biolabs firmographics
Firmographics- Name
- Ribbon Biolabs
- Legal name
- Ribbon Biolabs
- Website
- https://ribbonbiolabs.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ribbon Biolabs is a Vienna-based synthetic biology company that provides cell-free synthetic DNA products (MiroSynth™ and MiroMine™) to R&D teams in mRNA therapies, vaccines, cell and gene therapies, protein engineering, and gene editing.
- Ownership category
- akta.pro rank
Ribbon Biolabs industry classification
Industry- Product category
- Synthetic DNA / Synthetic Biology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), Plasmid DNA & mRNA Manufacturing Services (HLAAAKAE)
Keywords
Where Ribbon Biolabs is headquartered
LocationHeadquarters
- HQ city
- Vienna
- HQ country
- Austria
- HQ region
- Europe
Markets served
Ribbon Biolabs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- MiroSynth™ Cell-Free DNA Products: Sale of cell-free synthetic DNA products for research and development applications in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Ribbon Biolabs product offering
Product offeringCore offering
Ribbon Biolabs manufactures and supplies cell-free synthetic DNA products for biotechnology research and therapeutic development. Its core commercial product, MiroSynth™ Cell-Free DNA, delivers complex synthetic DNA sequences manufactured without bacterial cloning workflows, eliminating bacterial contaminants, residual host DNA, cloning delays, and design compromises from toxicity or instability. The company also offers MiroMine™, a kit-based in-lab cell-free DNA production system (currently in beta) that lets research teams build complex DNA on-site.
Product overview
Ribbon Biolabs offers a portfolio of cell-free synthetic DNA products centered around MiroSynth™ Cell-Free DNA and MiroMine™. MiroSynth™ is the core commercial product enabling complex DNA synthesis without bacterial workflows, while MiroMine™ is a kit-based solution in beta that allows in-lab cell-free DNA production. The company focuses on eliminating limitations of traditional bacterial-based DNA synthesis for applications in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.
Differentiator
Problem solved
Functional benefit
Brands
- MiroSynth™ Cell-Free DNA: Cell-free synthetic DNA product enabling faster progression into downstream applications with greater confidence, built without bacteria.
- MiroMine™
Products and services
- MiroSynth™ Cell-Free DNA Cell-free synthetic DNA product built without bacteria, enabling faster progression into downstream applications with greater confidence. Eliminates bacterial contaminants, residual host DNA, delays from cloning-based workflows, and design compromises from toxicity or instability. Designed for research teams in mRNA therapies, vaccine development, cell and gene therapies, protein engineering, and gene editing.
- MiroMine™ Kit-based, cell-free DNA production kit currently in beta that allows research teams to build complex DNA on-site without cloning or delays. Part of the MiroMine™ beta program for accessible kit-based, cell-free DNA synthesis.
Quantifiable outcome
- Eliminates bacterial contaminants and residual host DNA from synthetic DNA products
- +2 more outcomes
Companies that use Ribbon Biolabs
Customer profileSegments5 records
Ideal customer profiles1 record
Ribbon Biolabs technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Ribbon Biolabs partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
Ribbon Biolabs competitors and assessment
Company assessmentDirect peers
- GenScript: GenScript provides gene synthesis, plasmid manufacturing, and protein services to mRNA, cell therapy, and gene therapy developers. It is a direct competitor to Ribbon Bio's MiroSynth offering in therapeutic-grade DNA templates.
- Twist Bioscience: Twist Bioscience is a leading DNA synthesis provider offering both synthetic genes and an oligo pool platform via silicon-based synthesis. It directly competes with Ribbon Bio in selling synthetic DNA to mRNA, vaccine, and gene therapy R&D teams, though at much larger scale.
- Integrated DNA Technologies (IDT): IDT is one of the largest custom synthetic DNA/oligo providers serving academic, pharma, and gene synthesis customers globally. It overlaps directly with Ribbon Bio on gene synthesis for mRNA, gene editing, and synthetic biology workflows.
- Eurofins Genomics: Eurofins Genomics is a major European synthetic DNA and genomics services provider. As a European-headquartered competitor, it overlaps with Ribbon Bio's region and customer segments, particularly in research-grade gene synthesis.
- Synbio Technologies: Synbio Technologies provides gene synthesis, plasmid construction, and synthetic biology services. It competes with Ribbon Bio for gene synthesis orders from mRNA, gene therapy, and academic customers, particularly in Asia.
Emerging players
- DNA Script: DNA Script develops enzymatic (cell-free) DNA synthesis platforms and benchtop printers, overlapping with Ribbon Bio's MiroMine™ kit vision. Both target the same shift away from bacterial/clonal workflows.
- ATUM (formerly DNA2.0): ATUM provides gene synthesis, protein engineering, and synthetic biology tools to therapeutics and industrial biotech customers. It is a comparable niche competitor in synthetic DNA and protein engineering applications.
- Camena Bioscience: Camena Bioscience is an emerging synthetic biology company building enzymatic DNA synthesis technology. It competes with Ribbon Bio in the cell-free, high-fidelity synthetic DNA space serving therapeutics and synthetic biology customers.
- Ansa Biotechnologies: Ansa Biotechnologies is developing a novel enzymatic DNA synthesis approach for long, complex DNA sequences. It competes directly with Ribbon Bio's core value proposition of synthesizing complex constructs cell-free.
Broad incumbents
- New England Biolabs (NEB): NEB is a broad incumbent in molecular biology enzymes and reagents with adjacent offerings in DNA assembly and synthetic biology workflows. It is comparable as a foundational life-sciences tools supplier overlapping with Ribbon Bio's research customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Ribbon Biolabs social profiles
Digital presenceRibbon Biolabs compliance and trust
Trust signalCompliance1 record
Ribbon Biolabs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ribbon Biolabs leadership team
Management profileNumber of profiles
Profiles6 records
Ribbon Biolabs funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ribbon Biolabs M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ribbon Biolabs
What does Ribbon Biolabs do?
Ribbon Biolabs manufactures and supplies cell-free synthetic DNA products for biotechnology research and therapeutic development. Its core commercial product, MiroSynth™ Cell-Free DNA, delivers complex synthetic DNA sequences manufactured without bacterial cloning workflows, eliminating bacterial contaminants, residual host DNA, cloning delays, and design compromises from toxicity or instability. The company also offers MiroMine™, a kit-based in-lab cell-free DNA production system (currently in beta) that lets research teams build complex DNA on-site.
Is Ribbon Biolabs a public or private company?
Ribbon Biolabs is a private company. It is classified as venture growth investor backed and is currently operating.
When was Ribbon Biolabs founded?
Ribbon Biolabs was founded in 2018. It employs 51 to 100 people.
Where is Ribbon Biolabs based?
Ribbon Biolabs is headquartered in Vienna, Austria, in the Europe region.
How does Ribbon Biolabs make money?
One revenue line is on record: miroSynth™ Cell-Free DNA Products.
Who are Ribbon Biolabs's main competitors?
Direct peers on record are GenScript, Twist Bioscience, Integrated DNA Technologies (IDT), Eurofins Genomics and Synbio Technologies. Emerging players are DNA Script, ATUM (formerly DNA2.0), Camena Bioscience and Ansa Biotechnologies. New England Biolabs (NEB) is listed as a broad incumbent.
Does Ribbon Biolabs have an API?
No public API is recorded for Ribbon Biolabs.
What industry is Ribbon Biolabs in?
Ribbon Biolabs's product category is Synthetic DNA / Synthetic Biology. Its primary akta.pro industry code is HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 325414 and its SIC code is 2836.